New hope for rare skin cancer: experimental drug enters human trial
NCT ID NCT07047885
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests an investigational drug called ropeginterferon in 38 adults with cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Participants must have tried at least two prior treatments without success. The main goals are to find the safest dose and see if the drug can shrink or control the cancer. This is not a cure, but aims to manage the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo outsmart resistant T-Cell lymphoma?
- A microchip implanted in tumors could reveal which drugs work best
- Skin gel targets immune signals in rare lymphoma
- AI reads skin biopsies to spot hidden lymphomas
- Could an ALS drug clear the fog of chemo brain?
- Combination therapy aims to boost response in rare skin cancers